| Expression pattern: |
DN |
| Associated gene: |
IGF2BP1, HLA-F |
| Associated microRNA: |
- |
| Biological function: |
Inhibits NSCLC immune evasion and promotes cytotoxic activity of CD8+ T and NK cells; acts as a tumor suppressor. |
| Molecular mechanism: |
circCRIM1 binds IGF2BP1 (via RRM domains) and competitively inhibits IGF2BP1 binding to HLA-F transcripts, reducing HLA-F mRNA stability and expression. |
| Biological pathway or process: |
immune regulation (inhibits); apoptosis (promotes); mRNA stability (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; IHC (Immunohistochemistry); TUNEL; In Vivo Animal Model; Clinical Sample Validation; Cohort Study; Survival Analysis |
| Clinical significance: |
circCRIM1 expression is positively correlated with favorable prognoses; low circCRIM1 abundance may be associated with poor overall survival (OS) in NSCLC patients; may serve as a prognostic biomarker. |
| Description: |
circCRIM1 is down-regulated in NSCLC and functions as a tumor suppressor by inhibiting immune evasion. It binds the RBP IGF2BP1 and competitively reduces IGF2BP1-mediated stabilization of HLA-F mRNA, lowering HLA-F expression and enhancing CD8+ T/NK cytotoxic responses in vitro and in xenograft models. |
| Confidence score: |
0.8897 |